Please assess the completion status of the following clinical trial:

Trial Title: Can Earlier BCG Vaccination Reduce Early Infant Mortality? A Randomised Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~• All children registered during pregnancy will be eligible for the study provided they have not yet received BCG at the date of the home visit.~Exclusion Criteria:~* Children born outside the cluster, and returning more than 72 hours after the delivery~* Children that the nurse evaluates to die within the next 24 hours.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 72 Hours
- Healthy Volunteers: t

Study Arms:
- Intervention: BCG and OPV at home visits (Type: ACTIVE_COMPARATOR): Infants randomised to receive vaccines at home visits shortly after birth will receive one 0.05 ml dose of Mycobacterium bovis BCG live attenuated vaccine (BCG-Denmark 1331 (Statens Serum Institute) or BCG Japan (Japan BCG Laboratory) by intradermal injection in the left deltoid region. Dependent on national supply, infants will receive oral polio vaccine (OPV) at the time of BCG vaccination. For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth.
- Control: No vaccines at home visits (Type: NO_INTERVENTION): For all children, the nurse will perform umbilical cord and skin care, encourage skin-to-skin contact to keep the new-born warm, examine and weigh the child at a home visit shortly after birth. No vaccines will be administered at these home visits for children in the control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).